Bioventus Agrees To Nationwide Contract With Aetna Medicare Advantage Plans For DUROLANE For Knee Osteoarthritis; Terms Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
Bioventus (BVS) has secured a nationwide contract with Aetna Medicare Advantage Plans, owned by CVS Health (CVS), for its DUROLANE product used in the treatment of knee osteoarthritis. The financial terms of the agreement have not been disclosed.
December 06, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bioventus's nationwide contract with Aetna Medicare Advantage for DUROLANE could potentially increase the product's market penetration and sales, positively impacting BVS's revenue.
The contract with Aetna Medicare Advantage is likely to expand the availability of DUROLANE to a broader patient base under the Medicare Advantage plans, which could lead to increased sales and revenue for Bioventus. However, without financial terms, the exact impact on the bottom line remains uncertain.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
CVS Health, through its Aetna Medicare Advantage Plans, has added DUROLANE to its treatment offerings for knee osteoarthritis, potentially enhancing its competitive position in the Medicare Advantage space.
The addition of DUROLANE to Aetna's Medicare Advantage Plans could make the plans more attractive to potential members seeking osteoarthritis treatment, potentially improving customer acquisition and retention for CVS Health. The direct financial impact is less clear compared to BVS as it is one of many treatments offered.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70